We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-0.11%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.97B
AUM Growth
-$817M
Cap. Flow
-$41.1M
Cap. Flow %
-0.52%
Top 10 Hldgs %
77.13%
Holding
94
New
12
Increased
15
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$71.2M
2
BCYC
Bicycle Therapeutics
BCYC
+$67M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$43.3M
4
ABCL icon
AbCellera Biologics
ABCL
+$23.6M
5
DNLI icon
Denali Therapeutics
DNLI
+$21.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$242M
2
IMCR icon
Immunocore
IMCR
+$69M
3
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$20.9M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$14.6M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHL
76
DELISTED
Achilles Therapeutics
ACHL
$1.51M 0.02%
1,208,775
-894,017
-43% -$964K
GBIO
77
DELISTED
Generation Bio
GBIO
$1.51M 0.02%
+37,122
New +$874K
MURA
78
DELISTED
Mural Oncology
MURA
$1.09M 0.01%
+222,503
New +$1.08M
PFE icon
79
Pfizer
PFE
$143B
$971K 0.01%
35,000
– –
TARA icon
80
Protara Therapeutics
TARA
$214M
$801K 0.01%
199,671
– –
PMVP icon
81
PMV Pharmaceuticals
PMVP
$57.1M
$547K 0.01%
322,024
– –
ACRV icon
82
Acrivon Therapeutics
ACRV
$61.2M
$378K ﹤0.01%
+52,885
New +$245K
FHTX icon
83
Foghorn Therapeutics
FHTX
$278M
$302K ﹤0.01%
45,027
– –
CABA icon
84
Cabaletta Bio
CABA
$427M
$227K ﹤0.01%
13,331
– –
CATX icon
85
Perspective Therapeutics
CATX
$327M
$178K ﹤0.01%
14,979
-748,991
-98% -$6.39M
TYRA icon
86
Tyra Biosciences
TYRA
$1.85B
$174K ﹤0.01%
10,607
– –
SRZNW icon
87
Surrozen Inc Warrant
SRZNW
$36.6K
$25.2K ﹤0.01%
833,333
– –
DAWN
88
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-1,000,000
Closed -$14.6M
SPRY icon
89
ARS Pharmaceuticals
SPRY
$579M
– –
-2,006,451
Closed -$11M
WHWK
90
Whitehawk Therapeutics
WHWK
$181M
– –
-251,727
Closed -$508K
BCEL
91
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-2,177,499
Closed -$287K
GRCL
92
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-2,080,000
Closed -$20.9M
NVTA
93
DELISTED
Invitae Corporation
NVTA
– –
-1,764,546
Closed -$1.11M
MRTX
94
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-4,121,440
Closed -$242M
1 2 3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Baker Bros. Advisors held 94 positions worth $7.97B, down 9.3% from $8.79B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors's Q1 2024 filing shows 12 new, 15 increased, 7 reduced and 7 closed positions. Its largest new stake was Fate Therapeutics: 1,818,181 shares worth $13.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $242M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2024 buy was Fate Therapeutics: 1,818,181 shares worth $13.3M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q1 2024, an estimated $71.2M increase.
  • Baker Bros. Advisors's biggest Q1 2024 reduction was Immunocore, cutting an estimated $69M.
  • Baker Bros. Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $242M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $7.97B portfolio in Q1 2024.
  • Baker Bros. Advisors opened 12 new positions and closed 7 in Q1 2024.
  • Baker Bros. Advisors's portfolio value fell 9.3% quarter-over-quarter to $7.97B.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.